Obesity is a chronic, metabolic disease of complex and multiple causes leading to an imbalance between energy intake and output, and to the accumulation of large amounts of body fat. It is caused by inherited as well as acquired factors, including excessive food intake, sedentary lifestyle and unhealthy eating habits. During the past 20 years, obesity among adults has risen significantly with urbanization, economic development and market globalization. According to the World Health Organization (WHO) statements, more than one billion people worldwide are overweight or suffer from obesity, and the number of affected children has more than doubled since 1980 in the USA and Europe. In France, the latest data from Roche show that overweighting and obesity affect, respectively, more than 30% and 14.5% of adults (ObEpi-Roche, 2009).

But far more worrying are the increasing and acceleration of this problem into developing countries and, based on current trends, it is predicted that the levels of obesity will continue to rise unless action is taken now (McLellan, 2002). The consequences of obesity for adults are well known. Obesity contributes to the development of many diseases, including diabetes, hypertension, dyslipidemia (for instance, high total cholesterol or high levels of triglycerides), stroke, cardiovascular disease, and some cancers (Abelson and Kennedy, 2004). As a result, the obesity epidemic has prompted important efforts to develop safe and potent therapies. However, currently approved drugs for obesity such as appetite suppressants have limited efficacy and act acutely, with patients rapidly regaining weight after the cessation of treatment. The neurocytokine ciliary neurotrophic factor (CNTF) seems to deviate from this paradigm since its administration to rodents or patients maintains lowered body weights several weeks after terminating treatment (Lambert et al., 2001).

CNTF is a 200-amino acid cytokine that belongs to the IL-6 family. It is expressed in both the peripheral and the central nervous systems by neuronal and glial cells. Originally, CNTF was shown to promote the survival of ciliary ganglion neurons (Barbin et al., 1984; Helfand et al., 1976) and to play a major role in the modulation of appetite. Leptin decreases appetite and stimulates weight loss in rodents. Unfortunately, numerous forms of obesity in humans seem to be resistant to leptin action. The ciliary neurotrophic factor (CNTF) is a neurocytokine that belongs to the same family as leptin and that was originally characterized as a neurotrophic factor that promotes the survival of a broad spectrum of neuronal cell types and that enhances neurogenesis in adult rodents. It presents the advantage of stimulating weight loss in humans, despite the leptin resistance. Moreover, the weight loss persists several weeks after the cessation of treatment. Hence, CNTF has been considered as a promising therapeutic tool for the treatment of obesity and has prompted intense research aimed at identifying the cellular and molecular mechanisms underlying its potent anorexigenic properties. It has been found that CNTF shares signaling pathways with leptin and is expressed in the arcuate nucleus (ARC), a key hypothalamic region controlling food intake. Endogenous CNTF may also participate in the control of energy balance. Indeed, its expression in the ARC is inversely correlated to body weight in rats fed a high-sucrose diet. Thus hypothalamic CNTF may act, in some individuals, as a protective factor against weight gain during hypercaloric diet and could account for individual differences in the susceptibility to obesity.
the adult nervous system’s early response to lesions. Today, we know that its spectrum of functions is much broader since it includes the differentiation and/or survival of a variety of nervous cells such as motor neurons, oligodendrocytes and astrocytes (Hughes et al., 1988; Mayer et al., 1994; Sendtner et al., 1992).

In an initial clinical trial designed to test the efficacy of a CNTF analogue (Axokine™, Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of amyotrophic lateral sclerosis, a degenerative motor neuron disease, some patients suffered a substantial weight loss (Miller et al., 1996a; Miller et al., 1996b). Since then the mechanisms by which CNTF induces weight loss have been deciphered using animal models: CNTF mimics the ability of leptin to reduce food intake and to induce fat loss.

Indeed, similar to leptin, an adipocyte-secreted cytokine well known for its role in the long-term homeostasis of body weight, CNTF reduces appetite and body fat by providing a signal of energy intake and energy stores in the body to the arcuate nucleus (ARC) of the hypothalamus, a nucleus involved in hunger control (Markus, 2005). Adjacent to the third ventricle and to the median eminence, the ARC is ideally located to be a putative brain sensor of factors circulating in the blood and the cerebrospinal fluid. Notably, ARC integrates changes in circulating levels of nutrients and hormones such as leptin and insulin to respond to the energy body requirements (Schwartz, 2000). The ARC contains two main neuronal populations that exert contrary effects on energy balance. Neuropeptide Y (NPY)-producing neurons stimulate while pro-opiomelanocortin (POMC)-synthesizing neurons inhibit appetite. In rats, the anorexigenic action of exogenous CNTF has been associated to a decrease in NPY gene expression (Xu et al., 1998) and to an increase in POMC transcription (Ambati et al., 2007). Interestingly, the chronic administration of CNTF causes a decrease in food intake and body weight without inducing a rebound effect at the cessation of treatment, usually observed after a sustained reduction in caloric intake. This effect has been attributed to a resensitization of the ARC to leptin due to a CNTF-induced neurogenesis (Kokoeva et al., 2005).

Efforts to understand the mechanisms of action of CNTF in the nervous system have led to the identification of a three-component receptor complex for this cytokine. CNTF first binds to its specific CNTF receptor (CNTFRα), which does not play a direct role in signal transduction (Davis et al., 1993a). CNTFRα exists in two forms, membrane bound and soluble. The glycosyl phosphatidylinositol linkage of CNTFRα to the cell membrane can be cleaved by phospholipases releasing CNTFRα to act as a soluble protein (Taga et al., 1989). Then, binding of CNTF to the membrane-bound or soluble CNTFRα induces heterodimerisation of the “β” components of the receptor complex, gp130 and LIF receptor β (LIFRβ), which trigger intracellular signaling cascades (Davis et al., 1993b). The β components of CNTF receptor complex are preassociated in

![Figure 1. CNTF levels determined in the hypothalamus by Western blot negatively correlate with body weight in high-sucrose diet fed rats but not in control diet fed rats.](image-url)
Jak/Tyk tyrosine kinases. The inactive state with the cytoplasmic (Gloaguen et al. representative model of human obesity diet-induced obesity model, a more shown to bypass leptin resistance in through leptin-like pathways, has been is the fact that CNTF, which signals with leptin in the ARC. More interesting rodents, CNTF shares signaling cascades affected by PTP-1B over-expression, contrary to leptin, CNTF signaling was not associated to lower age at onset of eating disorders (Gratacos et al., 2010).

The anorexigenic properties of exogenous and endogenous CNTF have conferred to this cytokine a promising therapeutic potential in the treatment of obesity. However, the comprehension of the physiological significance of neural CNTF action is still incomplete because CNTF lacks a signal peptide (Sendtner et al., 1994), and thus may not be secreted by the classical exocytosis pathways. We have previously shown that CNTF distribution shares similarities with that of its receptor subunits in the rat ARC. Indeed, a majority of neurons and astrocytes express both CNTF and CNTFRα, and both β components of the receptor are ubiquitous in the rat ARC (figure 2) (Vacher et al., 2008). Thus, as previously envisaged in cell culture (Monville et al., 2002), a direct intracellular action may constitute a plausible mechanism of CNTF action. The involvement of such a process in the protective action of endogenous CNTF against diet-induced weight gain deserves further investigation. Nevertheless, these data could influence future drug discovery.

It is noteworthy that CNTF is highly expressed both in neurons and astrocytes of the hypothalamic nuclei that regulate energy balance, including the POMC anorexigenic neurons located in the ARC. To test the hypothesis of a relationship between the hypothalamic expression of CNTF and the control of energy homeostasis, the influence of a 6-week high-sucrose diet was studied on CNTF levels in the hypothalamus and the ARC in rats (Vacher et al., 2008). The high-sucrose diet induces a 2-fold increase in CNTF hypothalamic levels compared to control. Interestingly, while no association is observed between CNTF hypothalamic levels and body weight in control animals, a significant inverse correlation appears in rats fed the high-sucrose diet (figure 1). Indeed, in these conditions, animals with lower body weight exhibit higher amounts of CNTF in the hypothalamus. The variations in protein contents parallel those of mRNA levels. Moreover, the increase in CNTF expression is specific to the ARC, as evidenced by an immunohistochemical analysis. Thus, CNTF may be considered as an endogenous modulator of energy homeostasis in the ARC that possibly contributes to the protection of some individuals against diet induced weight gain. CNTF could account for individual differences in the susceptibility to obesity. Genetic polymorphisms studies corroborate the involvement of endogenous CNTF in the control of body weight. Indeed, it has been found that a null mutation in CNTF gene is associated with a significant increase in body mass in humans (Heidema et al., 2010; O’Dell et al., 2002), and that variants in CNTF or CNTFRα gene in humans are associated to lower age at onset of eating disorders (Gratacos et al., 2010).

Figure 2. Immunohistochemical detection of LIFR (green) in the rat arcuate nucleus (counterstaining with ethidium homodimer-2 in red). Confocal Z-stacks of three 0.5 μm-thick focal planes. 3V, third ventricle; ARC, arcuate nucleus; EtH-2, ethidium homodimer-2; LIFR, LIF receptor; ME, median eminence. Scale bars = 50 μm.
efforts for the development of new therapeutic targets against obesity.

REFERENCES


McLellan F. Obesity rising to alarming levels around the world. Lancet 2002; 359: 1412.


